Skip to main content
Erschienen in: Journal of the International AIDS Society 4/2010

Open Access 01.11.2010 | Oral presentation

0234. Mitochondrial ageing and antiretroviral therapy exposure

verfasst von: BAI Payne, CA Hateley, DC Samuels, IJ Wilson, M Santibanez-Koref, DA Price, PF Chinnery

Erschienen in: Journal of the International AIDS Society | Sonderheft 4/2010

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Purpose

Normal human ageing is thought to be driven by the progressive accumulation of molecular defects, including somatic mitochondrial DNA (mtDNA) mutations. Certain nucleoside analogue anti-retroviral drugs (NRTIs) are known to cause reversible mtDNA depletion, but it is unknown whether they affect age-associated mtDNA mutation.

Methods

We have recruited adult HIV-infected patients, all aged 50 years or under. Subjects were stratified according to cumulative (lifetime) exposure to those NRTIs previously implicated in disruption of mtDNA replication. Proportional level of the age-associated mtDNA common deletion (CD) was measured by means of a novel real-time PCR assay. Based on these and prior observations from our group, we then developed a validated model of mtDNA replication [1, 2], and incorporated a period of partial mtDNA replication failure due to NRTI exposure.

Results

Amongst all patients CD levels increased with subject age (r=0.467, p=0.005). Mean CD levels were significantly higher in NRTI-exposed than unexposed patients (mean log10(CD/mtDNA) ±SEM: NRTI+, -3.46 ±0.24? NRTI-, -4.62 ±0.29? p=0.006). Lifetime NRTI exposure was predictive of CD level (r=0.419, p=0.052). In silico modelling demonstrated that a finite period of partial replication failure was seen to lead to a period of mtDNA depletion during the exposure which corresponded to that expected for the relevant NRTI. During this period rapid expansion of pre-existing mtDNA deletion mutations was observed within individual simulated cells. This effect led to an increase in the proportion of cells with a functional mitochondrial defect which continued to increase after the period of exposure due to the continued effects of ageing. Longer exposure, exposure to more potent inhibitors of mtDNA replication and exposure later in life had the most profound effects on eventual cellular defect.

Conclusions

Cumulative exposure to certain NRTIs accelerates the accumulation of age-associated mtDNA deletion mutations, which appears to be irreversible, and mirrors that expected much later in life due to normal ageing. This effect could be caused simply by accelerated expansion of pre-existing age-associated somatic mtDNA mutations, mediated by finite periods of NRTI exposure. These data plausibly provide a novel biological mechanism for the phenomenon of accelerated ageing recently described in long-term treated HIV-infected patients.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Literatur
1.
Zurück zum Zitat Chinnery PF, Samuels DC: . Am J Hum Gen. 1999, 64: 1158-10.1086/302311.CrossRef Chinnery PF, Samuels DC: . Am J Hum Gen. 1999, 64: 1158-10.1086/302311.CrossRef
2.
Zurück zum Zitat Elson JL, Samuels DC, Turnbull DM, Chinnery PF: Am J Hum Gen. 2001, 68: 802-10.1086/318801.CrossRef Elson JL, Samuels DC, Turnbull DM, Chinnery PF: Am J Hum Gen. 2001, 68: 802-10.1086/318801.CrossRef
Metadaten
Titel
0234. Mitochondrial ageing and antiretroviral therapy exposure
verfasst von
BAI Payne
CA Hateley
DC Samuels
IJ Wilson
M Santibanez-Koref
DA Price
PF Chinnery
Publikationsdatum
01.11.2010
Verlag
BioMed Central
Erschienen in
Journal of the International AIDS Society / Ausgabe Sonderheft 4/2010
Elektronische ISSN: 1758-2652
DOI
https://doi.org/10.1186/1758-2652-13-S4-O28

Weitere Artikel der Sonderheft 4/2010

Journal of the International AIDS Society 4/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.